Pfizer Taps Into 'Doggybone DNA' For mRNA Vaccines, Gene Therapy Production
Targets Manufacturing Bottleneck
New enzyme-based approach could help make DNA-based therapy manufacturing faster, more scaleable and more reliable.
You may also be interested in...
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
The death in Pfizer’s Phase I study could reflect wider safety issues for AAV-based gene therapy and could spur intervention from regulators in 2022.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.